Anker SD, et al. - IIn this prospective registry study (CCM-REG), researchers determined the longer-term influence of cardiac contractility modulation (CCM) on hospitalizations and mortality in patients with New York Heart Association (NYHA) class III or IV symptoms, QRS < 130 ms and 25% ≤ left ventricular ejection fraction (LVEF) ≤ 45% (FIX-HF-5C study). Participants included 140 patients with 25% ≤ LVEF ≤ 45% on CCM therapy (CCM-REG_25-45) for clinical indications. Findings revealed CCM led to attenuation of cardiovascular and heart failure (HF) hospitalizations and improved Minnesota Living with Heart Failure Questionnaire (MLHFQ) and NYHA class in real-world experience; these benefits reported in this study were comparable to those of previous studies in subjects with 25% ≤ LVEF ≤ 45% and QRS < 130 ms.